Fluticasone furoate/umeclidinium/vilanterol single inhaler triple therapy for the management of moderate to severe COPD

Description

In this Product Explainer, Respiratory Physician Dr Martin MacDonald explains the role of single inhaler triple therapy containing fluticasone furoate/umeclidinium/vilanterol for the management of moderate to severe COPD (5 mins).

This educational activity was developed by Healthed at the request of and with funding from GSK.

PM-AU-FVU-VID-230011 Approved October 2023.

Icon 2

NEXT LIVE Webcast

:
Days
:
Hours
:
Minutes
Seconds
Prof Andrew Sindone

Prof Andrew Sindone

An Update on Heart Failure in Primary Care

Dr Gabby Mahoney

Dr Gabby Mahoney

Allergen Introduction – Practical Tips for GPs

Prof Kim Delbaere

Prof Kim Delbaere

Falls Prevention – A Practical, Evidence-Based Update on What Really Works

Dr Stephanie Daly

Dr Stephanie Daly

The New Dementia Test and How they Fit Into the Assessment and Management of the Patient with Cognitive Concerns

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

A/Prof Martin MacDonald

expert

A/Prof Martin MacDonald

Respiratory Physician, Monash Medical Centre; Head of Unit, Respiratory and General Medicine, Jessie McPherson Private Hospital

Date published: 20 November 2023